26 results about "Anti-agents" patented technology

Methods are provided for targeting cells for depletion, including without limitation tumor cells such as solid tumor cells, in a regimen comprising contacting the tumor and immune effector cells with an effective dose of an anti-MSDC agent that reduces the abundance, immunosuppressive activity, or tumor recruitment of CXCR2+ granulocytic-myeloid derived suppressor cells, for example, an inhibitor of CXCR2; in combination with an effective dose of an inhibitor of CD47 / SIRPα signaling.

This invention provides compounds and methods of application that possess both broad-spectrum antifungal activity and plant-induced resistance, belonging to the field of agricultural technology. It addresses the problem that "traditional pure immune inducers must be applied before disease onset, making it difficult to meet the full-cycle control needs of disease prevention and treatment in the field." Compared to the previously developed PC1 and PC20, the two compounds of this invention, 2,4-dibromo-6-nitrophenol and 7-deazon-2'-deoxy-7-iodoadenosine, can both inhibit the growth of rice blast fungus and significantly improve rice resistance to rice blast through foliar spraying, meeting the full-cycle control needs of disease prevention and treatment in the field. Furthermore, these two compounds can directly inhibit the growth of various fungal pathogens such as peanut white mold, tomato gray mold, wheat scab, rice bakanae disease, rice false smut, mango malformation, and banana wilt.

Some embodiments relate to a sustained release silica hydrogel composite comprising an anti-complement agent and methods of using same to treat ophthalmological conditions. The anti-complement agent may be an anti-C5 agent comprising a C5-specific aptamer.

The present disclosure relates to novel encapsulant film compositions that provide anti-PID properties while maintaining good cure, adhesion, volume resistivity properties. The composition comprises: a) a polyolefin polymer; b) an organic peroxide; c) a silane adhesion promoter; and d) a crosslinking aid; and e) an anti-PID agent.

Provided herein are uses of T cells, e.g., chimeric antigen receptor (CAR) T cells, for treating a tumor or a cancer (such as B cell related cancer, e.g., multiple myeloma) wherein the subject being treated has previously received a topoisomerase inhibitor, a proteasome inhibitor, an anti-CD38 agent, an immunomodulatory agent, or an anti-SLAMF agent therapy.

Provided are methods and compositions for treatment of angiogenic disorders using anti-VEGF agents. The anti-VEGF agents comprise VEGF binding domains and have the ability to bind vitreous. Provided are exemplary embodiments of Fc-IgG fusion proteins with VEGF binding domains with strong heparin-binding characteristics, strong inhibition of VEGF mitogenic activity, and improved pharmacokinetics, namely longer half-lives of the anti-VEGF agents and consequently less frequent dosing.

Compositions and methods for making and using anti-TLR9 agents, for example, monoclonal antibodies, TLR9-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-TLR9 agents, and methods of making and using the same.

To provide methods for treating diseases.SOLUTION: The present disclosure provides prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides, and compositions, methods and kits thereof. Such compounds can be useful for treating virus infections including human immunodeficiency virus. The compounds have the following formula (I). Provided herein are compounds functioning as antiviral agents (in some embodiments, as anti-HIV agents), pharmaceutical compositions comprising such a compound and optionally in combination with one or more (e.g., two, three or four) additional therapeutic agents, and methods for using such compounds and compositions. Embodiment of every disclosed compound includes pharmaceutically acceptable salts and stereoisomers thereof or a mixture of the stereoisomers.SELECTED DRAWING: None

The present disclosure relates to dosage regimes of anti-CD19 agents, in particular an anti-CD19×anti-CD3×anti-CD2 trispecific agent administered intravenously (i.v.) and subcutaneously (s.c.), and their use for treating diseases and disorders associated with expression of CD19 such as B cell malignancies, in particular relapsed and / or refractory B-cell malignancies.

The present application discloses a method for preventing and treating flue-cured tobacco virus disease, belonging to the field of plant protection. The method comprises (1) prevention: applying agents during the seedling stage, before transplanting, after transplanting, and during the field stage of tobacco growth; during the seedling stage: applying guanidine-copper acetate before thinning, replanting, and weeding; applying amino oligosaccharides and antiviral microbial agents before sealing the trays; applying cinclostrobin acetate solution after sealing the trays and before cutting the leaves; applying ningnanmycin and amino oligosaccharides before and after transplanting; applying insecticides mixed with plant resistance inducers, antiviral microbial agents, trace elements, and foliar fertilizers from one week after transplanting the seedlings to the stage of clustering; (2) treatment of the disease. The method prevents flue-cured tobacco virus disease by applying antiviral agents early in the whole growth stage of tobacco; and combining the antiviral agents with other specific agents to improve tobacco plant resistance, reduce the incidence of viral diseases, and improve the cure rate of viral diseases.

Compositions and methods for making and using anti-TLR9 agents, for example, monoclonal antibodies, TLR9-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-TLR9 agents, and methods of making and using the same.

The present invention relates to the treatment of locally advanced or metastatic urothelial carcinoma (mUC) in a patient suffering from FGFR altered mUC and having disease progression during or after one or more prior treatments comprising a checkpoint inhibitor, in particular an anti-PD-(L) 1 agent, with erdatinib.

The invention relates to the technical field of chemical production, in particular to high-dispersion pearlescent color oil for plastics and a preparation method thereof.The pearlescent color oil comprises 50%-97.5% of grease, 2%-50% of pearlescent toner and 0-10% of auxiliaries, the grease is a compound system of carbomer and the like, and the auxiliaries comprise a dispersing agent, an antioxidant and an anti-UV agent; the preparation method comprises the steps of raw material pretreatment, mixing, quantitative dispersion and curing post-treatment, and the dispersion uniformity coefficient sigma is controlled to be smaller than or equal to 0.3 by determining the dispersion rotating speed and time. Through raw material optimization and process quantitative regulation and control, the color oil dispersion stability is improved, the color oil can adapt to PP, PET, ABS and other plastics, the appearance can be ensured to be uniform and free of flow lines under the condition of low addition amount, and the color oil has good weather resistance. The process is high in operability, does not need special equipment, is suitable for industrial mass production, and provides a high-quality solution for plastic decoration.

This invention provides a halogenated flame-retardant V-0 polyolefin masterbatch for silane self-crosslinking materials and its preparation method. It comprises the following raw material components in parts by weight: 20-23 parts LDPE; 53-56 parts brominated flame retardant; 17-19 parts antimony flame retardant; 0.8-1.2 parts coupling agent; 2-3 parts UV stabilizer; 1.4-1.6 parts lubricant; and 0.4-0.5 parts antioxidant. The LDPE has a melt flow index of 1.5-2.5 g / 10 min. The combined use of these components produces a synergistic effect: even with relatively low addition levels, the resulting silane self-crosslinking material achieves a UL 94V-0 flame retardant rating, effectively reducing costs.

This disclosure relates to a novel encapsulant film composition that provides anti-PID properties while maintaining good performance in terms of curing, adhesion, and volume resistivity. The composition comprises a) a polyolefin polymer, b) an organic peroxide, c) a silane adhesion promoter, and d) a crosslinking aid, and e) an anti-PID agent.

This invention discloses an antibacterial ABS composite molded mirror cabinet and its manufacturing process, comprising a main cabinet, side cabinets, and a splicing cabinet. Fixing holes are provided on the inner sides of the main cabinet, side cabinets, and splicing cabinets. The front ends of the main cabinet and splicing cabinets are hinged to provide a main mirror door structure, and the front ends of the side cabinets are hinged to provide a folding mirror door structure. The antibacterial ABS composite molded mirror cabinet and its manufacturing process utilize ABS substrate combined with a specific UV-resistant agent and chemically bonded silver ion antibacterial agent to achieve long-lasting anti-yellowing and durable antibacterial properties, solving the problem of mold growth in bathrooms. The cabinet body adopts an external splicing and internal one-piece molding design, balancing dimensional flexibility and leak-proof performance, and is enhanced with a 3D mirror door for a better user experience. Through multi-step process optimization, stable product quality and high production efficiency are ensured. Compared to wooden and ordinary plastic bathroom cabinets, it combines environmental friendliness and safety, superior mechanical properties, and no usage limitations, effectively solving the technical pain points of existing products.

A multi-layer coating with antibacterial and anti-COVID properties which is usable in various environments, including hospitals, and which can be easily deposited by spraying on different surfaces and capable of providing an effective removable barrier against pathogens and bacteria, which waterproof coating is characterized in that it uses graphene nanoparticles as an antibacterial and anti-COVID agent deposited by spraying a polymer material as a host layer on the surface to promote the dispersion and uniform surface distribution thereof, the polymer material being directly adhered by spraying to the surface to be coated or sprayed on a second polymer, in turn sprayed on the surface to be coated, which is used as an element to promote the adhesion of the first polymer forming the antibacterial and anti-COVID coating to the surface to be coated.

This invention relates to the field of polymer composite materials technology, specifically providing a long-lasting antistatic ABS material and its manufacturing method. By weight, the material comprises the following raw materials: 100 parts ABS resin, 3-5 parts antistatic modifier, 1 part UV stabilizer, 1.5 parts polymer auxiliary conductive filler, and 0.2 parts antioxidant; wherein the antistatic modifier is a PEG-b-PS diblock copolymer. This invention achieves physical entanglement and permanent anchoring of molecular chains through the good compatibility between the PS segment of the PEG-b-PS block copolymer and the ABS matrix, while simultaneously utilizing the microphase separation of its PEG segments to construct hydrophilic conductive channels within the matrix; combined with the electronic conductive network of the auxiliary conductive filler, a dual "ion-electron" synergistic conductive mechanism is formed. This material possesses long-lasting, migration-resistant, abrasion-resistant, and aging-resistant antistatic properties, while causing minimal damage to the mechanical properties of the ABS matrix, maintaining high appearance, and achieving a surface resistivity of up to 10 Ω·cm. 9 -10 11 Ω / □, especially suitable for high-end cleanroom scenarios such as photomask protective film boxes.

The present application discloses a polyvinyl chloride material, which comprises, by mass: 55 to 65 parts of polyvinyl chloride, 10 to 25 parts of a plasticizer, 1 to 6 parts of a stabilizer, 0.5 to 1.5 parts of an anti-UV agent, 0.5 to 1.5 parts of a lubricant, 4 to 8 parts of a flame retardant, 5 to 15 parts of an ethylene-vinyl acetate copolymer elastomer, 1 to 3 parts of a processing aid, and 0.2 to 0.5 parts of a toner; the anti-UV agent comprises a combination of 2-(2H-benzotriazole-2-yl)-4,6-bis(1-methyl-1-phenylethyl)phenol and 3,5-di-tert-butyl-4-hydroxybenzoate hexadecyl. The addition of ethylene-vinyl acetate copolymer as part of the plasticizer system reduces the risk of adhesive performance degradation caused by plasticizer precipitation and mixing with hot-melt adhesive, thereby extending the service life of the fixed position; the use of two anti-UV agents in combination can effectively improve the weather resistance of the material, reduce UV-induced yellowing, and thus extend the service life of the transparent optical fiber broadband.

Provided herein is a method for treating DLL3-expressing cancers using an anti-DLL3 antigen-binding protein administered subcutaneously. The anti-DLL3 antigen-binding protein comprises the amino acid sequence of SEQ ID NO: 13 and the amino acid sequence of SEQ ID NO: 22, and may be administered to a subject once every two weeks (Q2W), once every three weeks (Q3W), or once every four weeks (Q4W).

The present disclosure provides pharmaceutical compositions and methods thereof for the prevention or treatment of ocular neovascularization, such as AMD, in a subject, by administering to the subject a pharmaceutical composition comprising a rAAV vector having a nucleic acid sequence that encodes an anti-VEGF agent.

Compositions and methods for treating, inhibiting, preventing or reducing disorders and diseases in a subject by administering one or more anti-c-MYC agents are disclosed. In one aspect, a subject having a c-Myc-mediated disease, disorder or condition is treated with a compound of the disclosure including a compound selected from Formula (I), (I) wherein R is H, an in vivo cleavable linker or group, or a leaving group in aqueous solution and R1 and R2 are independently, H, alkyl, an aryl, a substituted alkyl, a substituted phenyl, a substituted aryl, or a combination thereof.

The present invention is directed to methods for treating diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), wet age-related macular degeneration (AMD) and / or retinal vein occlusion (RVO) in a patient or subject in need comprising administering an effective amount of at least one anti-DME agent selected from the group consisting of desipramine, protriptyline, cyclosporin A, crisaborole, empagliflozin, nitroxolone, suprofen, sulfisoxazole, methapyrilene, phentolamine, naphazoline or a pharmaceutically acceptable salt thereof, preferably at least one agent selected from the group consisting of desipramine, nitroxolone, methapyriline, phentolamine, napthazoline and their pharmaceutically acceptable salts.

Treatment combinations are provided for FOLR1-binding immunoconjugates (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), platinum-based agents, and / or doxorubicin. Methods for administering said combinations to treat cancers, such as ovarian cancer, with increased clinical efficacy and / or reduced toxicity are also provided.

The disclosure relates to compositions and methods for treating DLL3-expressing cancers by administration of an anti-DLL3 antigen-binding agent (e.g., tarlatamab) to a subject once every four weeks (Q4W).

Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), platinum-based agents, and / or doxorubicin are provided. Methods of administering the combinations to treat cancer, e.g., ovarian cancer, with higher clinical efficacy and / or reduced toxicity are also provided.